Summary
The product Caber-0.25 (Cabergoline 0.25 mg), manufactured by Intex Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number T-19009, was submitted by Intex Pharma and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the concentration of Cabergoline at 0.30 mg, which is 20% above the labeled claim of 0.25 mg.
The testing process began on 8 October 2024, with the sample received on 22 October 2024, and analysis completed on 28 October 2024. While the results confirm a slightly higher concentration than labeled, scrutiny of manufacturer-submitted samples remains essential to ensure reliability. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Intex Pharma
- Product Name: Caber-0.25 (Cabergoline 0.25 mg)
- Active Ingredient: Cabergoline
- Batch Number: T-19009
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #51239
- Testing Ordered: 8 October 2024
- Sample Received: 22 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Intex Pharma (Manufacturer)
- Analysis Paid For By: Intex Pharma (Manufacturer)
Testing Results
- Specification: 0.25 mg (as stated on the label)
- Measured Concentration: 0.30 mg
- Accuracy: 120% (20% above the label claim)
Verification Details
Verification URL: https://janoshik.com/tests/51239_CVQPY63R3PZR
Evaluation of Manufacturer-Submitted Testing
This analysis confirms that Cabergoline is present at 0.30 mg, which is slightly above the expected concentration. While this deviation does not necessarily indicate a quality issue, ensuring consistent dosing is crucial for consumer trust and regulatory compliance. Since Intex Pharma submitted and funded the test, careful evaluation is needed to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple samples.
Conclusion
The analysis confirms that Caber-0.25 (Cabergoline 0.25 mg) contains 0.30 mg of Cabergoline, which is 20% above the labeled claim. While this batch exhibits high purity and slightly elevated potency, ongoing testing is necessary to ensure consistent dosing across different production runs. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
